Figure 1From: A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma Kaplan-Meier Analysis of Time to Progression (TTP) and Time to Symptomatic Progression (TTSP). The median TTP was 57 days (1.9 months) and the TTSP was 358 days (11.7 months).Back to article page